KNOT Offshore Partners LP Earnings Release-Interim Results for the Period Ended June 30, 2026

KNOT Offshore Partners LP (KNOP) reported Q2 2026 earnings with $96.8M revenue, $3.4M net income, and $57.6M Adjusted EBITDA. The company declared a $0.075 quarterly distribution and extended charters for several vessels. KNOP also refinanced $225M in debt and acquired the Hedda Knutsen shuttle tanker for $24.4M, subject to adjustments. The fleet operated at 96.8% utilization, and the company has secured 97% charter coverage for H2 2026 and 87% for H2 2027.

Original reporting
Published Sep 3, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$KNOP
Bullish
high confidence
Mentioned
$KNOP
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$KNOPBullishHigh
01

Why it matters

The earnings beat and cash distribution provide a short‑term catalyst, while long‑term charter extensions support future cash flow stability.

02

Market read

Earnings release offers a clear trading signal for KNOP; sector peers may see spillover effects.

03

What to watch

Upcoming credit facility refinancing and vessel acquisitions could increase leverage and risk.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings released today

Background

KNOT Offshore Partners LP (NYSE:KNOP) reported its Q2 2026 interim results, highlighting revenue, EBITDA, cash distribution, fleet utilization, and recent charter extensions.

Company-level read

Ticker impact

$KNOPBullishHigh confidence
Context

Q2 2026 earnings release with revenue $96.8M, adjusted EBITDA $57.6M and cash distribution of $0.075 per unit.

Expected impact

Potential modest price rise on the day of release as investors digest the solid performance and distribution.

Evidence & confidence

Revenue and EBITDA beat expectations for a small‑cap offshore shuttle tanker partnership; cash distribution adds yield appeal.

Market effects

Positive signal for offshore shuttle tanker sector and related offshore oil production services.

May boost sentiment for North Sea and Brazil offshore markets where the fleet operates.

Limited to energy logistics niche; modest broader market effect.

Counterpoint

If offshore oil demand softens, the high utilization may be temporary and earnings could be unsustainable.

Key entities

  • Shell

    Extended charter for Live Knutsen, adding revenue visibility.

  • Eni

    Signed new three‑year time charter for Hilda Knutsen.

Related articles

$KNOPMed

KNOT Offshore Partners LP (KNOP): Financial results for H1 2026

KNOT Offshore Partners LP (KNOP) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 KNOT OFFSHORE PARTNERS LP EARNINGS RELEASE—INTERIM RESULTS FOR THE PERIOD ENDED JUNE 30, 2026 KNOT Offshore Partners LP (NYSE:KNOP): Financial Highlights For the three months ended June 30, 2026 (“Q2 2026”), KNOT Offshore Partners LP (“KNOT Offshore Partners,” “we” o

$HYMed

Hyster-Yale’s (HY) Bookings Boom Meets A Widening Loss

Hyster-Yale (HY) reported Q2 results with bookings up 106% YoY to $680M, but a net loss of $31.6M. Revenue rose 2% QoQ to $812.9M, and operating cash flow turned positive at $17M. Management expects full-year bookings to exceed 2025, but warns of slow margin recovery due to competitive pricing and tariffs.

$MNDYHighAI 8/10

Why Monday.com Stock Popped in August

Monday.com (MNDY) stock rose 16% in August, despite initial investor concerns over its Q2 results. Revenue grew 22% YoY to $365M, and adjusted net income increased 13% to $65.6M. The company provided optimistic guidance for Q3 and 2026. A strong earnings report from Salesforce later in the month boosted investor sentiment in the CRM sector, benefiting Monday.com.

$AQSTMed

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.